- Home
- FSFG vs IPHA Comparison
FSFG vs IPHA Comparison
Compare FSFG & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSFG
- IPHA
- Stock Information
- Founded
- FSFG 2008
- IPHA 1999
- Country
- FSFG United States
- IPHA France
- Employees
- FSFG N/A
- IPHA N/A
- Industry
- FSFG Savings Institutions
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- FSFG Finance
- IPHA Health Care
- Exchange
- FSFG Nasdaq
- IPHA Nasdaq
- Market Cap
- FSFG N/A
- IPHA 150.9M
- IPO Year
- FSFG 2008
- IPHA 2019
- Fundamental
- Price
- FSFG $23.74
- IPHA $1.93
- Analyst Decision
- FSFG Buy
- IPHA Strong Buy
- Analyst Count
- FSFG 1
- IPHA 1
- Target Price
- FSFG $30.00
- IPHA $11.50
- AVG Volume (30 Days)
- FSFG 11.5K
- IPHA 50.9K
- Earning Date
- FSFG 01-28-2025
- IPHA 03-20-2025
- Dividend Yield
- FSFG 2.51%
- IPHA N/A
- EPS Growth
- FSFG 201.94
- IPHA N/A
- EPS
- FSFG 2.74
- IPHA N/A
- Revenue
- FSFG $73,624,000.00
- IPHA $36,202,722.00
- Revenue This Year
- FSFG N/A
- IPHA N/A
- Revenue Next Year
- FSFG $2.77
- IPHA $101.65
- P/E Ratio
- FSFG $8.73
- IPHA N/A
- Revenue Growth
- FSFG N/A
- IPHA N/A
- 52 Week Low
- FSFG $14.55
- IPHA $1.29
- 52 Week High
- FSFG $30.94
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- FSFG 39.99
- IPHA 56.50
- Support Level
- FSFG $23.01
- IPHA $1.72
- Resistance Level
- FSFG $26.12
- IPHA $1.92
- Average True Range (ATR)
- FSFG 0.77
- IPHA 0.10
- MACD
- FSFG -0.05
- IPHA 0.02
- Stochastic Oscillator
- FSFG 28.30
- IPHA 100.00
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.